Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 8Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Depression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Anxiety Disorders 1Anus Neoplasms 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Psychiatric Rehabilitation × Clear all
NCT02440737 2019-10-18

NEST

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
67 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡